Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
22.12 USD | -0.23% | -0.76% | +504.44% |
04-02 | North American Morning Briefing : Stocks Seen -2- | DJ |
04-01 | HC Wainwright Downgrades Landos Biopharma to Neutral From Buy | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 193.1 | 20.13 | 11.41 | 69.3 | - | - |
Enterprise Value (EV) 1 | 193.1 | 20.13 | 11.41 | -3.2 | 39.3 | -32.2 |
P/E ratio | -4.71 x | -0.51 x | -1.05 x | -9.43 x | -13.2 x | -18.6 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 10.7 x | - | - | - | - | - |
EV / Revenue | 10.7 x | - | - | - | - | - |
EV / EBITDA | -5,000,806 x | - | - | - | - | - |
EV / FCF | -7,022,694 x | -439,763 x | - | - | - | - |
FCF Yield | -0% | -0% | - | - | - | - |
Price to Book | 2.53 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 4,024 | 4,025 | 3,117 | 3,126 | - | - |
Reference price 2 | 48.00 | 5.001 | 3.660 | 22.17 | 22.17 | 22.17 |
Announcement Date | 24/03/22 | 23/03/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | 18 | - | - | - | - | - |
EBITDA | - | -30.54 | -38.62 | - | - | - | - | - |
EBIT 1 | -13.29 | -30.68 | -38.82 | -40.56 | - | -26.4 | -45 | - |
Operating Margin | - | - | -215.64% | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -30.14 | -38.42 | -39.28 | - | -26.4 | -45 | - |
Net income 1 | - | -30.14 | -38.42 | -39.28 | -21.94 | -26.4 | -46.15 | -87.4 |
Net margin | - | - | -213.46% | - | - | - | - | - |
EPS 2 | -21.60 | -24.70 | -10.20 | -9.800 | -3.500 | -2.350 | -1.685 | -1.190 |
Free Cash Flow | - | -23.14 | -27.5 | -45.78 | - | - | - | - |
FCF margin | - | - | -152.78% | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 24/07/20 | 31/03/21 | 24/03/22 | 23/03/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | -20.34 | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -12.4 | -20.4 | -14.95 | -11.27 | -7.829 | -6.513 | -6.479 | - | - | - | -5.5 | -6.4 | -6.9 | -7.6 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -12.6 | -20.1 | -14.86 | -11.28 | -7.896 | -5.232 | -6.034 | - | - | - | -5.5 | -6.4 | -6.9 | -7.6 |
Net income 1 | -12.6 | -20.1 | -14.86 | -11.28 | -7.896 | -5.232 | -6.034 | -3.922 | -5.86 | -6.119 | -5.5 | -6.4 | -6.9 | -7.6 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -3.200 | -5.200 | -3.700 | -2.800 | -2.000 | -1.300 | -0.9000 | -0.6300 | -0.9400 | -1.840 | -0.8800 | -0.6300 | -0.4800 | -0.5300 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 15/11/21 | 24/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 23/03/23 | 12/05/23 | 09/08/23 | 09/11/23 | 21/03/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | 28.1 | - | - | - | 72.5 | 30 | 102 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | -23.1 | -27.5 | -45.8 | - | - | - | - |
ROE (net income / shareholders' equity) | - | -345% | - | - | - | - | - |
ROA (Net income/ Total Assets) | -74.6% | -62.4% | - | - | - | - | - |
Assets 1 | 40.41 | 61.61 | - | - | - | - | - |
Book Value Per Share | -42.30 | 18.90 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | 0.18 | 0.44 | - | - | - | - | - |
Capex / Sales | - | 2.44% | - | - | - | - | - |
Announcement Date | 31/03/21 | 24/03/22 | 23/03/23 | 21/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+504.44% | 69.3M | |
+22.00% | 46.4B | |
-1.69% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.03% | 26.01B | |
-19.40% | 19.52B | |
+30.16% | 12.43B | |
-0.16% | 12.18B | |
-0.69% | 12.13B |
- Stock Market
- Equities
- LABP Stock
- Financials Landos Biopharma, Inc.